ICAM-1 on cDC1 promotes the survival of stem-like memory CD8 T cells generated in tumor draining lymph nodes

Dendritic cells (DCs) cross-present tumor antigens to cognate T cells in tumor-draining lymph nodes (TdLNs). ICAM-1 is a key adhesion molecule involved in the formation of diverse cell-cell contacts between immune cells as well as blood vessels and stromal cells. We have recently found that ICAM-1 expressed by lymph node DCs can stabilize antigen-dependent contacts with naïve CD8 T cells but is dispensable for CD8 T cell differentiation and proliferation into effector and memory lymphocytes generated in various models of vaccination and virus infections. To follow the role of DC ICAM-1 in CD8 proliferation and differentiation triggered by tumor expressed neoantigens, we orthotopically implanted breast cancer E0771 cells expressing the model OVA neoantigen in immunocompetent mice conditionally deleted of ICAM-1 expression in all CD11c expressing -conventional DCs (cDCs), monocyte derived DCs (mDCs) and pDCs. Strikingly, in contrast to viral challenges, the tumor challenge drove naïve tumor-antigen specific CD8 differentiation almost exclusively into T-stem-like central memory T cells (TSL) with high expression of L-selectin (CD62L), PD-1, and the transcription factor TCF-1 implicated in T cell stemness and proliferative potential. Early CD8 activation and differentiation into these central memory T cells remained normal in these mice. This indicated that tumor antigen transfer by migratory DCs to lymph node DCs and its initial cross presentation to naïve T cells do not require ICAM-1 expression by all types of DCs. Furthermore, deletion of ICAM-1 selectively in XCR1 conventional type 1 dendritic cells (cDC1), specialized in tumor antigen uptake and cross priming of tumor specific T cells in tumor draining lymph nodes, did not impair early tumor specific CD8 activation and differentiation. Nevertheless, the maintenance of resident self-renewing stem-like tumor specific CD8 memory cells in the tumor draining lymph nodes was diminished in the absence of ICAM-1 expression by cDC1. We currently explore the possibility that ICAM-1 deficiency in these DCs impairs the stability of survival niches generated by Ag-specific CD8 TSL and cDC1. Our results highlight a specialized instructive role of cDC1 ICAM-1 in antigen dependent maintenance of a pool of lymph node stem-like tumor-specific lymphocytes. This pool is a main source of tumor specific CD8 T cells which egress the draining lymph nodes and home into primary tumors, where they differentiate into short-lived terminally differentiated effector T cells (CTLs) critical for tumor eradication.

Authors

Institutions

Publication Details

Journal
South East European Journal of Immunology
Published
2025-03-25
DOI
https://doi.org/10.3889/seejim.2025.6089
Citations
1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ICAM-1 on cDC1 promotes the survival of stem-like memory CD8 T cells generated in tumor draining lymph nodes

R. Alon, Marina Kizner, Stav Kozlovski, Moshe Biton et al.
1 citations
South East European Journal of Immunology
CAR-T cell therapy research
1.05
article

ICAM-1 on cDC1 promotes the survival of stem-like memory CD8 T cells generated in tumor draining lymph nodes

R. Alon, Marina Kizner, Stav Kozlovski, Moshe Biton, Nehora Levi
article en
1 citations

Abstract

Dendritic cells (DCs) cross-present tumor antigens to cognate T cells in tumor-draining lymph nodes (TdLNs). ICAM-1 is a key adhesion molecule involved in the formation of diverse cell-cell contacts between immune cells as well as blood vessels and stromal cells. We have recently found that ICAM-1 expressed by lymph node DCs can stabilize antigen-dependent contacts with naïve CD8 T cells but is dispensable for CD8 T cell differentiation and proliferation into effector and memory lymphocytes generated in various models of vaccination and virus infections. To follow the role of DC ICAM-1 in CD8 proliferation and differentiation triggered by tumor expressed neoantigens, we orthotopically implanted breast cancer E0771 cells expressing the model OVA neoantigen in immunocompetent mice conditionally deleted of ICAM-1 expression in all CD11c expressing -conventional DCs (cDCs), monocyte derived DCs (mDCs) and pDCs. Strikingly, in contrast to viral challenges, the tumor challenge drove naïve tumor-antigen specific CD8 differentiation almost exclusively into T-stem-like central memory T cells (TSL) with high expression of L-selectin (CD62L), PD-1, and the transcription factor TCF-1 implicated in T cell stemness and proliferative potential. Early CD8 activation and differentiation into these central memory T cells remained normal in these mice. This indicated that tumor antigen transfer by migratory DCs to lymph node DCs and its initial cross presentation to naïve T cells do not require ICAM-1 expression by all types of DCs. Furthermore, deletion of ICAM-1 selectively in XCR1 conventional type 1 dendritic cells (cDC1), specialized in tumor antigen uptake and cross priming of tumor specific T cells in tumor draining lymph nodes, did not impair early tumor specific CD8 activation and differentiation. Nevertheless, the maintenance of resident self-renewing stem-like tumor specific CD8 memory cells in the tumor draining lymph nodes was diminished in the absence of ICAM-1 expression by cDC1. We currently explore the possibility that ICAM-1 deficiency in these DCs impairs the stability of survival niches generated by Ag-specific CD8 TSL and cDC1. Our results highlight a specialized instructive role of cDC1 ICAM-1 in antigen dependent maintenance of a pool of lymph node stem-like tumor-specific lymphocytes. This pool is a main source of tumor specific CD8 T cells which egress the draining lymph nodes and home into primary tumors, where they differentiate into short-lived terminally differentiated effector T cells (CTLs) critical for tumor eradication.

South East European Journal of ImmunologyVol. 8(CITIM)
Weizmann Institute of Science (IL)
Openalex Percentile: Top 24%
CAR-T cell therapy research
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.